Navigation Links
ISTO Technologies to Present at OneMedPlace Emerging Company Finance Conference

ST. LOUIS, Jan. 6 /PRNewswire/ -- ISTO Technologies, Inc. announced today that it will participate in the 2nd Annual OneMedPlace Emerging Company Finance Conference in San Francisco, CA from January 13-14, 2009. Mitchell Seyedin, Ph. D., President and CEO of ISTO, will present on Tuesday, January 13th at 10:15 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell St. The conference will bring together promising emerging healthcare and life science companies with strategic and venture investors focused on new technologies, emerging and micro cap public companies. Information about OneMedPlace and the conference may be found at

ISTO is a privately-held orthobiologics company based in St. Louis, MO. The Company's discrete cell-based and biomaterial platforms encompass a number of technological breakthroughs that are poised to advance the practice of medicine by offering solutions for unmet and/or largely unsatisfied clinical needs in large orthopedic markets. ISTO's mix of clinical stage, development stage and marketed products includes DeNovo(R) ET, engineered cartilage to repair and restore joint function in the knee, NuQu(TM), a cell-based injectable formulation of juvenile chondrocytes for nucleus regeneration of the spinal disc and InQu(R), an osteobiologic bone graft Substitute and extender.

About ISTO

ISTO Technologies, Inc. is developing and marketing clinical solutions for sports medicine, spinal therapy, and trauma. ISTO's products are intended for the repair and regeneration of damaged or injured cartilage and bone. For additional information on ISTO, please visit our website at or contact Scott Gill, Chief Financial Officer, at +1-314-995-6049.

SOURCE ISTO Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
2. BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative
3. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
6. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
7. Cascades Technologies, Inc. and SAIC Team on $19 Million Contract with National Institutes of Health
8. Life Science Alley: R&D Makes German Medical Technologies Top in Europe
9. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
10. GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.
11. Sigma-Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT(R) Single-Wall Carbon Nanotubes
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of the ... brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing ... to its list of well-respected retailers. This list includes such fine stores as ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):